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Abstract 
Recent ICH quality guideline updates introduced the enhanced drug development which is 
based on Quality by Design approach. For this a Quality Risk Management has to be 
conducted based on scientific knowledge. Information gaps are closed through analysis of 
molecules with domain-specific modifications. The aim of this thesis was to evaluate methods 
to prepare a model IgG1 for such studies. The antibody fragments F(ab’)2, LHF, Fab and Fc 
and the Fc-glycosylation cleaved IgG with residual N-acetylglucosamine were selected. A 
representative IgG1 was digested with the recently discovered enzymes IdeS, Kgp, IgdE and 
EndoS2 and the digestion products were purified with common biotechnological down-stream 
methods. The F(ab’)2 was successfully isolated with a yield of 55% and a purity of 96%. After 
an initial digestion parameter optimization the LHF, Fab and Fc could be generated and an 
isolation method was established. A following scale-up was unsuccessful, due to 
reproducibility issues. A promising alternative was identified. The enzymatic glycan cleavage 
and product isolation was successful with a yield of 80% and a purity of 99%. 
Zusammenfassung 
Die kürzlich von der ICH aktualisierten Qualitätsrichtlinien führten den erweiterten 
Wirkstoffentwicklungsvorgangs ein, welcher auf dem Quality-by-Design Prinzip basiert. Dazu 
wird ein Risikomanagement, basierend wissenschaftlichen Fakten durchgeführt. Um 
Informationslücken zu schliessen müssen proteindomänenspezifisch veränderte Moleküle 
untersucht werden. Das Ziel dieser Arbeit war die Evaluation von Methoden zur Vorbereitung 
eines Modell IgG1 für solche Studien mit minimaler unspezifischer Veränderungen. 
Ausgewählt wurden die IgG-Fragmente F(ab‘)2, LHF, Fab und Fc und das Fc-Polysaccharid 
gespaltene IgG mit restlichem N-Acetylglucosamin. Ein repräsentatives IgG1 wurde mit den 
kürzlich entdeckten Enzymen IdeS, Kgp, IgdE und EndoS2 verdaut und mittels üblichen 
biotechnologisch Reinigungsmethoden aufgereinigt. Das F(ab‘)2 Fragment konnte mit einer 
Ausbeute von 55% und Reinheit von 96% isoliert werden. Nach einer initialen Optimierung der 
Verdauungsparameter konnte das LHF, Fab und Fc erfolgreich hergestellt und eine Methode 
zur Fragmentisolation gefunden werden. Die Herstellung einer grösseren Menge war erfolglos, 
jedoch konnte eine alternative Lösung identifiziert werden. Die enzymatische Spaltung des 
Polysaccharids und Isolation war erfolgreich mit einer Ausbeute von 80% und einer Reinheit 
von 99%.  
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Abbreviations 
Table 1: Abbreviations. 
Acronym Description 
Ab Antibody 
ADCC Antibody-dependent cellular cytotoxicity 
CDR Complementary determining region 
CE Capillary electrophoresis 
CH1 First constant heavy chain domain 
CH2 Second constant heavy chain domain 
CH3 Third constant heavy chain domain 
CL Constant light chain domain 
DB Digestion buffer 
DP Drug product 
Fab Fragment antigen binding 
Fc Fragment crystallizable 
FcRn Neonatal Fc receptor 
FcγR IgG-Fc receptor 
Fuc Fucose 
Gal Galactose 
GAS Group A Streptococcus 
GlcNAc N-acetylglucosamine 
HC Heavy chain 
HPLC High performance liquid chromatography 
ICH International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use 
Ig Immunoglobulin 
IgdE Immunoglobulin G degrading enzyme of S. agalactiae 
LC Light chain 
Mab Monoclonal antibody 
Man Mannose 
NeuGc N-glycosylneuraminic acid 
NR Non-reducing 
PAGE Polyacrylamide gel electrophoresis 
PD Pharmacodynamics 
 viii 
PK  Pharmacokinetics 
QbD Quality by Design 
QRM Quality risk management 
Rgp Arginine gingipain 
RMT Relative migration time 
Rt Room temperature 
SDS Sodium dodecyl sulfate 
VH Variable heavy chain domain 
VL Variable light chain domain 
 
Amino acids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Amino acid properties Venn diagram [1]. 
 
Amino acid 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
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1 Introduction 
With the creation of the first monoclonal antibody (mab) in 1975 a new era of pharmaceutical 
development was initiated [2]. The mab technology increased therapeutic options and opened 
new treatment opportunities for diseases with an unmet medical need, such as cancer, 
immunological disorders, chronic inflammatory disease, infectious disease and many more [3]. 
Because mabs have a higher target specificity and reduced systemic toxicity compared to prior 
predominant small molecular drugs, focus of drug research and development slowly shifted 
toward this technology [4]. In 1986, the first mab was licensed [2,5]. Sixteen years later, in 
2002 the first human mab was approved by the U.S. Food and Drug Administration for 
pharmaceutical use in humans [3]. In 2014 the annual global mab market was approximately 
$20 billion, generated by roughly 30 products [2] and is estimated to grow to $125 billion with 
around 70 products on the market by the year 2020 [5]. In parallel with the transition from small 
to large molecular drug research and development, regulatory authorities introduced the new 
quality guidelines Q8 – Q12 for drug development, listed in Table 2 [6–8]. 
Table 2: List of new ICH quality guidelines. 
ICH Guideline Topic 
Q8(R2) Pharmaceutical development 
Q9 Quality Risk Management 
Q10 Pharmaceutical Quality System 
Q11 Development and Manufacture of Drug Substance 
Q12 Technical and Regulatory Considerations for Pharmaceutical Product 
Lifecycle Management 
The new guidelines propose an enhanced approach for drug development compared to the 
traditional. Where the traditional way defines set values and operational ranges for process 
parameters, based on tests and reproducibility studies to reach their acceptance criteria the 
enhanced approach integrates quality directly into the process [8]. This is achieved by 
elaborating a quality risk management (QRM) based on scientific evaluations throughout the 
whole product lifecycle, a so called quality by design (QbD) approach. The QbD, illustrated in 
Figure 2, includes a summary of characteristics of a drug product (DP) for its ideal quality, the 
so called quality target product profile (QTPP). The QTPP contains for example information 
regarding the indication, the mechanism of action, the dosage form or the dosage strength [9]. 
Based on the QTPP a critical quality attribute (CQA) assessment is performed, listing any 
physical, chemical, biological, or microbiological property of a DP having an influence on the 
quality with regard to activity/potency, pharmacokinetics/-dynamics (PK/PD), immunogenicity 
and/or safety. Examples of CQAs are viral impurity, host cell proteins, glycosylation or high 
molecular weight species. Afterwards operation parameters affecting CQAs, the critical 
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process parameters (CPP), are defined and tested by a design of experiment (DoE). Based 
on the results of these experiments, the criticality of the CQAs is adapted. Examples for CPPs 
are: temperature, time and pH. Based on the findings a working area of each CPP is defined, 
called the design space. At last a control strategy is introduced, ensuring the defined quality of 
the final DP. The whole process is maintained and updated through the whole lifecycle and 
should lead to an improved product understanding and ultimately higher patient safety [10–
14]. 
 
Figure 2: Illustration of the Quality by Design strategy [15,16]. 
To conduct a QRM potential risks are identified first, their likelihood is rated and the 
consequences are assessed. Based on those points an impact factor for each risk is calculated 
and an appropriated follow-up action is evaluated. Such can be “no action required”, “further 
investigation required”, “close monitoring” or “risk prevention”. The basis for such a risk 
identification for quality attributes emerges from four sources, illustrated in Figure 3: literature 
& in-silico data, in-house knowledge and product comparison, project related experimental 
data and specific clinical experience. The information availability is usually high for literature & 
in-silico data and decreases for in-house knowledge & product comparison. Project related 
experimental data and specific clinical expertise, which have both a high certainty score and 
cost & time investment, are often only available in late development phases. Therefore, the 
relation of effort to information gain has to be evaluated thoroughly. 
Quality target 
product 
profiles 
(QTPP) 
Critical 
process 
parameters 
(CPP) 
Critical quality 
attributes 
(CQA) 
Design 
Space 
Control 
Strategy 
Verification 
Validation 
Iterative process throughout the lifecycle 
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Figure 3: Potential information sources for the quality risk management [15]. 
The risks considered for impact assessment of quality attributes during drug development are 
divided into four categories, listed in Figure 4. 
 
Figure 4: The four quality categories for the risk assessment quality attributes [15,17–20]. 
This QbD approach slowly finds its way into pharma companies, where chemistry, 
manufacturing and control strategies are adapted and updated accordingly. For an adequate 
risk evaluation a fundamental molecule, mechanism and process understanding is necessary. 
During the CQA assessment related to the active pharmaceutical ingredient in-depth 
understanding of potential structural and molecular modifications and their impact are 
evaluated. As literature and in-silico data are generally rated quiet uncertain and are often not 
Literature & 
in-silico data 
In-house knowledge 
& product comparison 
Project related 
experimental 
data 
Specific 
clinical 
experience 
Cost and duration 
Certainty 
Availability 
Biological activity/potency describes the ability of a molecule/drug to 
induce a certain response in a biological system at a defined 
concentration [17]. 
Pharmacokinetics (PK) is the study of progression of a drug during 
absorption, distribution, metabolism and excretion. Pharmacodynamics 
(PD) is the study of the biological effect caused by the drug at the site of 
action [18]. 
Immunogenicity describes the ability of a substance inducing an 
immunological reaction in an organism This includes the formation of 
anti-drug antibodies [19]. 
Safety according to the World Health Organization are biological, 
chemical or physical agents or operations that are reasonably likely to 
cause illness or injury [20]. 
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even available for new biological entities, molecular entity-specific in-house knowledge has to 
be expanded and tools to gain project-specific experimental data have to be established. So 
far biopharmaceuticals have been exposed to controlled stressed conditions, like heat, 
oxidation or shearing stress, for a defined period of time and degradation products were 
analyzed. This approach may introduce multiple, uncontrolled modifications leading to vague 
conclusions. Therefore, the development of new tools to modify a drug very specific (and 
prevent undesired modifications) is necessary. 
The topic of this study is to start establishing tools for the CQA assessment of 
biopharmaceuticals. Potential modification are for the most part dependent on the molecular 
structure of the drug substance and may vary from one project to another. As a starting point 
the immunoglobulin G (IgG) 1 subclass was used in this thesis. IgG1 is currently the most used 
subclass of mabs in drug development. A possibility of targeted modification is obtained 
through enzymes. Especially in protein-related sciences enzymes offer a wide variety of 
applications. Unfortunately, commonly used endoproteinase, such as trypsin, Lys-C, papain 
or pepsin still tend to undesired over-digestion. In recent years new endoprotease were 
discovered which promise to cleave IgGs sequence specific without the risk of over-digestion 
[21–24]. The goal of this thesis is to screen and improve the enzymatic digestion of a model 
IgG1 to obtain Fab, Fc, LHF and F(ab’)2 fragments, respectively the chitobiose cleaved IgG, 
shown in Figure 5, and isolated the corresponding products. Undesired modifications have to 
be prevented as far as possible. For a copy of the objective setting agreement please see 
appendix page X. 
 
Figure 5: Selected digestion products to be evaluated during the master thesis including their final purpose in the 
CQA assessment. 
F(ab‘)2 
 Bivalent binding (potency)  Monovalent binding (potency) 
 Monovalent binding (potency) 
LHF 
Fab Fc 
(Fuc-)GlcNAc-IgG 
 Glycosylation pairing (PK/PD) 
 Fc methionine oxidation distribution 
 Change in higher order structure 
 FcRn, FcγR and C1q binding (PK/PD) 
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2 Theoretical background 
2.1 Antibodies 
Antibodies (Ab), also called immunoglobulin (Ig), are glycoproteins and play an essential role 
in the adaptive immune system. Abs are naturally either transmembrane proteins, as B-cell 
receptors or soluble proteins released from plasma cells after an antigen recognition. Special 
properties of such Abs are the high specificity and affinity to bind a certain antigen and initiate 
an effector mechanism [25]. 
2.1.1 Structure 
The basic structure of an Ab, illustrated in Figure 6, is Y-like shaped and consists of the stem, 
the so called fragment crystallizable (Fc) responsible for the effector function (explained in 
chapter 2.1.4) and the two arms, the so called fragment of antigen-binding (Fab) responsible 
for the specific antigen binding [26]. Abs are axial symmetrical hetero-tetramers containing two 
light chains (LC) and two heavy chains (HC). The LC consist of two domains of roughly 
12.5 kDa, the variable (VL) and constant (CL) domain. The HC consists of four domains, also 
one variable (VH) and three constant domains (CH1, CH2 and CH3). The two HC are interlinked 
between CH1 and CH2, in the so called hinge-region via disulfide bridges [25,27]. Similarly, the 
LC and the HC are liked via a disulfide bridge in the Fab region [25]. Additionally, each domain 
contains an intra-chain disulfide bond [28]. The CH2 bears an N-glycosylation at position 
Asn297, which plays an important role for the effector function, protein stability and the ability to 
aggregate [29,30]. The highly specific binding ability of Igs origins from the hypervariable 
regions within the variable region, the so called complement determining region (CDR) [25]. 
Each variable domain contains three CDRs and the CDR of the HC and LC lie close together 
through the three-dimensional arrangement forming the so called antigen-binding pocket [31]. 
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Figure 6: Illustration of the IgG1 structure with light chain in apricot and heavy chain in blue. 
 
 
Figure 7: Ig Fab with CDR in red and a hapten as 
epitope [32]. 
 
Figure 8: 3D surface structure of an IgG1 [33]. 
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In humans there are two different types of LCs, the κ and the λ chain and five different types 
of HCs, the γ, δ, ε, α and μ chain. Depending on the HC type, antibodies are classified into five 
classes or isotypes, namely IgG, IgD, IgE, IgA and IgM [25–27]. IgG have the highest half-life 
of roughly three weeks and are therefore the most interesting class for therapeutic applications 
[25]. The IgG class is further divided into four subclasses [25,27,34,35], depending on the 
preferable antigen target, hinge region length, disulfide connection [26,28], serum 
concentration, half-life, placental transfer potential, complement activation and Fc receptor 
binding. Those subclasses are numbered ascending from highest to lowest relative abundance 
(γ1, γ2, γ3, γ4) in human serum. IgG1 is usually found in the highest relative abundance in the 
human serum compared to other subclasses and targets mainly soluble and membrane 
proteins. Additionally, it has compared to other subclasses a unique disulfide connection 
between LC and HC [34] and binds efficiently to the IgG-Fc receptor (FcγR) [36]. 
2.1.2 Fragment nomenclature 
In Figure 9 common antibody fragments are listed. 
 
Figure 9: Nomenclature of common IgG fragments [37–42]. 
Immunoglobulin G 
IgG 
Fragment antigen binding 
Fab 
F(ab‘)2 
Fragment crystallizable 
Fc 
Fc/2 
Large hinge fragment [40] 
LHF 
Fab‘ Reduced/half IgG 
rIgG/hIgG 
Fd‘ 
The term Fabc is rarely used and can have two different meanings. Either as 
equivalent for the intact IgG [37,42] or the IgG without CH3 domains [41]. 
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2.1.3 Glycosylation 
Protein glycosylation is a highly complex post-translational modification but crucial for folding, 
conformation, stability & half-live, solubility, pharmacokinetics, biological activity and 
immunogenicity [29,43]. Ig of the subclass γ1 undergo glycosylation in the endoplasmic 
reticulum and Golgi network and contain a conserved glycosylation at approximate position 
Asn297 of both CH2 domains in the Fc region. Roughly 20% of mabs contain an additional N-
glycosylation in the variable region. Usually glycosylation of Abs consists of a complex bi-
antennary glycan with core-fucosylation [44]. An illustration of transgenic animal respectively 
Chinese hamster ovary cell N-glycosylation structures is shown in Figure 10. Minor size and 
structural differences of the glycan from one protein to another lead to an unequal mixture, 
which is called glycoform heterogeneity [44,45]. Specifically for IgG the glycosylation has an 
effect on thermo-, unfolding- and protease-stability, impacts the aggregation tendency [46] and 
influences the effector functions, especially the antibody-dependent cell cell-mediated 
cytotoxicity (ADCC) and the complement dependent cytotoxicity (CDC) [29,46,47]. 
 
Figure 10: Fc glycosylation structure of transgenic animal/Chinese hamster ovary cells. 
2.1.4 Mechanism of action 
Abs can have different effects on an antigen. Important for a functional Ab is the ability to bind 
a certain epitope with the binding pocket and initiate an effector function from the Fc region. 
With both of these properties Abs act as adapter and bring antigen and the immune cell 
together. Especially IgG1 and IgG3 are known to initiate such effector mechanisms [34]. 
Therapeutic mabs on the other hand usually do not depend on an effector function and in some 
cases those are even undesired. A summary of the most important effector functions are listed 
in the appendix on p. II. 
2.2 Enzymes 
Enzymes are proteins with a wide function of catalyzing bio-chemical reactions in an organism. 
Some enzymes catalyze a certain reactions high specific and under physiological conditions. 
Fc glycosylation of Chinese hamster ovary cells 
Chitobiose core 
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Enzymes also have a high relevance in industrial and diagnostic applications. A summary of 
commonly used enzymes for the mab analytic is listed in the appendix on p. III. 
2.2.1 Immunoglobulin-degrading enzyme of Streptococcus pyogenes 
Name Immunoglobulin-degrading 
enzyme of Streptococcus 
pyogenes 
Abbreviation IdeS, streptococcal Mac-1 
Catalytic type Cysteine [48] 
Family Protease C66 [49]; CA clan 
[50] 
Organism Streptococcus pyogenes 
Molecular weight 36.2 kDa [50] 
Molar absorbance 1.362 (calculated) [51] 
 
Figure 11: Illustration of IdeS. 
Streptococcus pyogenes is a bacteria causing strep throat and impetigo in humans [52]. 
Recent studies revealed its secreted cysteine endopeptidase (IdeS or streptococcal Mac-1) to 
naturally protect the bacteria from the host’s immune system by cleaving surrounding Ig at the 
lower hinge region. 
 
Figure 12: IgG fragmentation of IdeS. 
IdeS contains similar structural features as papain but shows only minor sequence homology. 
Both can structurally be divided into a left-hand (L) and right-hand (R) domain and the catalytic 
site is located at the interface in between. High specificity of substrate recognition towards the 
hinge region of IgG is a unique feature of IdeS. So far only few accepted sequences of the Ig 
hinge region have been identified, shown in Figure 13 [50]. This high specificity, which prevents 
over-digestion is exploited for bioanalytical applications. 
  
Catalytic domain 
L R 
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Figure 13: Accepted sequence for the IdeS cleavage. Identical amino acid in black, closely chemically similar in 
blue, weakly chemically similar in sienna and non-similar in apricot. 
The catalytic mechanism proposed for the IdeS digestion is similar to the one of the papain 
cysteine protease superfamily, forming a thiolate-imidazolium ion with the catalytic dyad Cys94 
and His262, shown in Figure 14 [50].  Through proton transfer from His262 to Cys94 the enzyme 
is activated.  The thiolate of Cys94 attacks the carbonyl of the substrate and forms an 
enzyme-substrate complex.  The scissile peptide bond of the substrate is broken and the C-
terminal fragment is released, where the remaining chain forms together with the enzyme a 
thioester, the so called acyl-enzyme intermediate.  The thioester is hydrolyzed in a 
subsequent step and the N-terminal chain is also released [53]. 
 
Figure 14: Proposed catalytic cycle of the IdeS cleavage. 
Asp284 and Asp286, close to the catalytic pocket, have been identified to have a positive impact 
on the catalytic activity, by facilitating the correct three-dimensional orientation resp. creating 
 240 250 
 ....|............|.... 
IgG1 ...CPAPELLG | GPSVF... 
IgG2 ...---APPVA | GPSVF... 
IgG3 ...CPAPELLG | GPSVF... 
IgG4 ...CPAPEFLG | GPSVF... 
Accepted IdeS cleavage sequence 
  
 
 
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a suitable electrostatic milieu. Additionally, Lys84, which is stabilized through the hydrogen 
bond-salt link of Asp286, forms together with the active site Cys94 a stabilizing pocket for the 
substrate, the so called oxyanion hole [50]. This is illustrated in Figure 15. 
 
Figure 15: Catalytic pocket and stabilizing effects. 
Initial kinetic studies showed a non-Michaelis-Menten behavior, but a curve of positive 
cooperativity [54]. Later studies revealed an underlying two-step Michaelis-Menten kinetics, 
where the first reaction is 100 times faster than the subsequent [55]. 
Genovis®, a life science company, offers recombinant IdeS in various forms, e.g. as lyophilisate 
(FabriCATOR®), immobilized on agarose (FragIT™) or in combination with a CaptureSelect™ 
column (FragIT™ kit) including digestion procedure. 
2.2.2 Lysine gingipain of Porphyromonas gingivalis 
Name Lysine gingipain 
Abbreviation Kgp 
Enzyme class EC 3.4.22.47 [54] 
Catalytic type Cysteine 
Family Protease C25; CD clan [53] 
Organism Porphyromonas gingivalis 
Molecular weight 187 kDa (native) [56] 
48 kDa (recombinant; catalytic 
and immunoglobulin 
superfamily-like domain) 
[53,57] 
Molar absorbance 1.971 (recombinant, 
calculated) [58] 
 
Figure 16: Illustration of recombinant Kgp. 
 
The periodontal disease is a wide spread bacterial infection of the gums and the bacteria 
supposedly to be the main cause is Porphyromonas gingivalis. P. gingivalis expresses two 
Hole with catalytic pocket 
Immunoglobulin superfamily- 
like domain 
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types of cysteine peptidase gingipain, the lysine (Kgp) and the arginine gingipain (RgpA and 
RgpB). These two enzymes contribute to a large part to the extracellular proteolytic activity 
responsible for its high virulence [57]. Structurally Kgp consists of five domains; the signal 
peptide, a pro-domain, the Lys-specific catalytic subdomain, an immunoglobulin superfamily-
like domain, and the C-terminal domain [53,57]. Kgp cleaves multiple substrates after Lys [53] 
and also plays an important role in evading the host’s immune system by degrading Ig at the 
upper hinge region, illustrated in Figure 17 [54]. 
 
Figure 17: IgG fragmentation of Kgp and IgdE. 
For Fc glycosylated IgG1 only one cleavage site, above the hinge region, has been identified, 
shown in Figure 18. For IgG1 without glycosylation a second cleavage site in the Fc region 
was observed [22]. Also IgG3 have been reported to be cleaved by Kgp but not as specific as 
IgG1. For IgG2 and IgG4 no cleavage sites have been identified [54]. 
 
Figure 18: Accepted Kgp cleavage sequence of IgG1 [22]. 
The proposed mechanism is similar to IdeS Cys/His dyad involving Cys477 and His444, but 
experiments have shown the importance of Asp388 for the catalytic cleavage [57]. Typical for 
cysteine proteases is an activity increase in a mild reducing environment, like glutathione or 
cysteine [53]. Kinetic studies revealed that the digestion does not follow the Michaelis-Menten 
kinetic, but rather a mechanism of positive cooperativity [54], usually meaning the first ligand 
binding to the enzyme simplifies a subsequent binding [59]. Similar to IdeS, Kgp kinetics could 
also underlie a consecutive two-step Michaelis-Menten kinetic, but this theory was not tested 
yet. It is reported that the digestion can be stopped by drastically decrease pH or addition of 
iodoacetic acid resp. Nα-Tosyl-L-lysine chloromethyl ketone [54]. The mayor advantage of Kgp 
over commonly used papain or Lys-C is the high specificity without the risk of over-digestion. 
Genovis® offers a recombinant Kgp in a kit including a cysteine solution as reducing agent, 
called GingisKHAN®.  
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2.2.3 Immunoglobulin G degrading enzyme of Streptococcus agalactiae 
Name Immunoglobulin G-
degrading Enzyme 
Abbreviation IgdE 
Catalytic type Cysteine 
Family Protease C113, CA clan [60] 
Organism Streptococcus agalactiae 
Molecular weight 70 kDa (recombinant)  
Molar absorbance 0.584 (calculated) [61]  
Figure 19: Illustration of IgdE. 
The immunoglobulin G degrading enzymes (IgdE) of the Streptococcus species, known for 
their virulence in several species, were recently discovered and have been identified to help 
the bacteria evade the host’s immune system by degrading surrounding Ig. Exceptional for 
those enzymes is their high specificity towards IgG of the streptococci’s main host and distinct 
cleavage site. One IgdE, degrading human IgG1, origins from S. agalactiae and cleaves the 
Ab similar to papain, above the hinge region, shown in Figure 20, but without further cleavage. 
The involved mechanism is the same as for Kgp and is formed by the catalytic triad Cys302 
His333 and Asp348. Several applicable cysteine protease inhibitors like, Z-LVG-CHN2 and 
iodoacetamide have been reported [36,49,55]. 
 
Figure 20: Accepted IgdEagalactiae cleavage sequence of human IgG1 [36]. 
2.2.4 Endo-beta-N-acetylglucosaminidase of Streptococcus pyogenes 
Name Endo-beta-N-
acetylglucosaminidase 
Abbreviation EndoS2 
Family Glycoside hydrolases 18 
Organism Streptococcus pyogenes 
group A (GAS) (Serotype 
M49) [62] 
Molecular weight 95 kDa (native) [63] 
92 kDa (recombinant) [24] 
Molar absorbance 1.044 (calculated) [64] 
 
Figure 21: Illustration of EndoS2. 
 
Streptococcus pyogenes, as explained in chapter 2.2.1, possesses another way to evade the 
human immune system. The bacteria produces, next to IdeS, the endoglycosidase EndoS. 
Catalytic pocket 
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This enzyme is hydrolyzing the glycosidic bond between the two acetylglucosamine (GlcNAc) 
in the chitobiose core structure of IgG impairing an effector function and increasing bacterial 
survival [62]. 
 
Figure 22: Chemical structure of the chitobiose core. 
The EndoS is conserved in almost all identified S. pyogenes serotypes with the exception of 
serotype M49 GAS strain. The serotype M49 GAS expresses instead the enzyme EndoS2, with 
similar function but a sequence homology of only 37% [63]. Both enzymes cleave complex 
type glycans. However EndoS2 cleaves in addition also high-mannose and hybrid type glycans 
[65]. All human IgG subclasses and Abs of several species, such as mouse, rat, monkey, 
sheep, goat, cow and horse have been identified as substrate. Importantly, the enzyme works 
only on native proteins, which indicates a protein-protein interaction. Through a sequence 
alignment and later active-site mutation the catalytic Glu186 and several Trp have been 
identified to be of importance for the digestion [62]. Next to IgG only one other protein, the α1-
acid glycoprotein, has been identified to act as substrate and therefore EndoS and EndoS2 do 
not show general chitinase activity. 
 
Figure 23: Chitobiose cleavage of EndoS2. 
Genovis® offers an EndoS (IgGZero™) and an EndoS2 (GlycINATOR®) ready-to-use kit, 
containing the corresponding enzyme with a poly-his tag as lyophilisate or immobilized on 
agarose. 
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2.3 Kinetics model for the Kgp digestion 
To simplify result comparison and reduce enzyme consumption a model was applied for 
studies on Kgp. This model is based on the reaction kinetics of a consecutive first-order 
reaction as described below [66]. The kinetic order was not experimentally determined but 
assumed as a first order reaction. 
 
Figure 24: Proposed consecutive reaction scheme of an IgG and Kgp. 
The IgG reacts in a first reaction step with the kinetic constant k1 to the LHF and a Fab and in 
a subsequent step with k2 to two Fabs and one Fc. k1 is calculated using Equation 1 and kinetic 
constants for different digestion parameter are compared. The higher the kinetic constant the 
faster the digestion. 
Equation 1: Determination of the kinetic constant k1 [66]. 
𝑘1 =
1
𝑡
ln
[𝐴]0
[𝐴]𝑡
 
It is assumed that k1 and k2 are almost the same, as neither the enzyme nor the substrate 
change by a lot. Only the accessibility of the substrate of the second reaction is presumably 
higher compared to the first and k1 is therefore slightly smaller than k2. 
𝑘1 ≈ 𝑘2 
𝑘1 < 𝑘2 
The molar concentration of the intermediate product is calculated according to Equation 2. 
Equation 2: Calculation of the intermediate product concentration [I]. 
[𝐼] =
𝑘1
𝑘2 − 𝑘1
(𝑒−𝑘1𝑡 − 𝑒−𝑘2𝑡)[𝐴]0 
The molar concentration of the product is calculated according to Equation 3. 
Equation 3: Calculation of the product concentration [P]. 
[𝑃] = (1 +
𝑘1𝑒
−𝑘2𝑡 − 𝑘2𝑒
−𝑘1𝑡
𝑘2 − 𝑘1
) [𝐴]0 
The time point where the intermediate product is highest is calculated according to Equation 
4. 
k1 k2 
A I P 
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Equation 4: Calculation of the time point of the maximal intermediate concentration is reached. 
𝑡[𝐼]𝑚𝑎𝑥 =
1
𝑘1 − 𝑘2
ln (
𝑘1
𝑘2
) 
Transformed back to purity the digestion progress is expected to behave as shown in Figure 
25. 
 
Figure 25: Simulated Kgp digestion progress based on a consecutive first-order kinetic. 
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3 Methods and materials 
3.1 Instruments, consumables, reagents and software. 
High performance liquid chromatography (HPLC) was performed on instruments from Agilent, 
the capillary electrophorese (CE) on BECKMAN-COULTER instruments and the content was 
measured on a Nanodrop™ by Thermo Scientific. All enzyme were purchased from Genovis®. 
Analytical data evaluation was performed on Chromeleon™ 6.8. A detailed list of all 
instruments, consumables, reagents and software can be found in the appendix on p. IV - VI. 
3.2 Model antibody 
During this studies a model IgG1 was used. The used mab is developed by Novartis and 
blinded in this report for the protection of the company’s intellectual property. It is simply 
referred as mIgG1 standing for model IgG1. The mIgG1 belongs to the IgG1 subclass with a κ 
LC and the standard mab solution is formulated at approximately 200 mg/mL in 5 mM L-
histidine/L-histidine hydrochloride at pH 5.8. 
3.3 Buffer preparation 
Table 3: List of used buffer. 
Name Composition 
CaptureSelect™ binding buffer 10 mM sodium phosphate, 150 mM sodium chloride pH 7.4 
CaptureSelect™ elution buffer 100 mM glycine pH 3.0 
CE-SDS NR gel buffer Beckman Coulter gel buffer, Cat. no. 391163 
CE-SDS NR sample buffer 100 mM tris base, 10 g/L SDS, pH 7.00 
CE-SDS red gel buffer Beckman Coulter gel buffer, Cat. no. 391163 + water 
(1:1.2) 
CE-SDS red sample buffer 50 mM tris base, 5 g/L SDS, pH 8.5 
cOmplete™ solution 1 Tablet in 50 mL Kgp DB 
EndoS2 digestion buffer 10 mM sodium phosphate, 150 mM NaCl, pH 7.4 
Formulation buffer 5 mM L-histidine/L-histidine-HCl pH 5.8 
IdeS digestion buffer 10 mM sodium phosphate, 137  mM NaCl, 2.7 mM KCl, 
pH 6.0 
IgdE digestion buffer 150 mM sodium phosphate pH 7.0 
Kgp digestion buffer 100 mM tris pH 8.0/7.3/6.0 
Protein L binding buffer 20 mM sodium phosphate, 150 mM NaCl, pH 7.2 
Protein L elution buffer 100 mM sodium citrate, pH 2.0 – 3.5 
Reducing solution 20 mM cysteine 
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3.4 Physicochemical methods 
Several physicochemical techniques were used for sample analysis and fragment isolation. 
Detection was always by UV and the digestion progress was evaluated according to purity by 
capillary electrophoresis (CE). 
3.4.1 Cation exchange chromatography 
Cation exchange chromatography (CEX) is a liquid chromatography technique and belongs to 
the ion-exchange chromatography. It is used to separate species with a different net surface 
charge on an ionic stationary phase. It was used to detect the rate of deamidation, shown in 
Figure 26, by monitoring purity of the acidic species. 
 
Figure 26: Deamidation of asparagine. 
During this study a salt based separation gradient was applied with parameter listed in Table 
4. 
Table 4: Applied CEX parameter. 
Parameter Setting 
Sample injection concentration 1 mg/mL 
Sample injection volume 50 μL 
Sample temperature 5°C 
Mobile phase A 25 mM sodium phosphate, pH 6.0 
Mobile phase B 25 mM sodium phosphate, 250 mM sodium chloride, pH 6.0 
Flow rate 1.0 mL/min. 
Column ProPac™ WCX-10 
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Column temperature 25°C 
Detection 220 nm 
Gradient Time in min %B 
 0 10 
 30.0 37 
 30.1 100 
 32.0 100 
 32.1 10 
 40.0 10 
An example chromatogram is displayed in Figure 27. 
 
Figure 27: Example cation exchange chromatogram. 
3.4.2 Size exclusion chromatography 
Size exclusion chromatography (SEC) separates species according to their hydrodynamic 
radius. This technique was used to separate and collect the native IgG1, LHF and Fab fractions 
using the parameters listed in Table 5. 
Table 5: Applied SEC parameter for fraction collection. 
Parameter Setting 
Sample injection amount 40 – 400 μg 
Sample injection volume 10 – 100 μL 
Sample temperature 5°C 
Mobile phase 150 mM potassium phosphate, pH 6.5 
Flow rate 0.4 mL/min. 
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Column TSKgel G3000SWXL; 2 – 3 columns in series 
Column temperature 30°C 
Detection 210 nm 
Run time 55 – 85 min 
 
3.4.3 Capillary electrophoresis – sodium dodecyl sulfate 
CE is, like the polyacrylamide gel electrophoresis (PAGE), a physicochemical separation 
technique but instead of a planar gel the separation occurs in a thin capillary [67]. Sodium 
dodecyl sulfate (SDS) denatures the protein and ensures a similar charge to mass ratio of all 
proteins, thus migration time increases with higher molecular weight. The technique is superior 
to SEC in regard to peak resolution of fragments but has the disadvantage that sample 
fractionation is not possible. 
Non-reducing conditions 
For non-reducing (NR) CE-SDS, the protein sample was pre-diluted to 6 mg/mL in water, 20 μL 
of this solution were further diluted in 75 μL sample buffer and 5 μL 250 mM iodoacetamide 
solution were added for alkylation. Afterwards the protein was denatured at 70°C for 10 min, 
the solution was cooled down to room temperature (rt), centrifuged and analyzed by CE-SDS 
with parameters listed in Table 6. 
Table 6: List of CE-SDS NR parameter. 
Parameter Setting 
Auto sampler temperature 20°C 
Injection type Outlet 
Injection voltage 5 kV 
Capillary length 30 cm 
Capillary diameter 50 µm 
Capillary temperature 25°C 
Polarity Positive 
Voltage 15 kV 
Detection 214 nm 
An example CE-SDS NR electropherogram of the Kgp digestion, with assigned peaks is shown 
in Figure 28. 
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Figure 28: Example CE-SDS NR electropherogram of the Kgp digestion. 
Reducing conditions 
For reducing (red) CE-SDS the protein sample was pre-diluted to 6 mg/mL in water, 20 μL of 
this solution were further diluted in 75 μL sample buffer and 5 μL 2-mercaptoethanol were 
added for reduction. Afterwards the protein was denatured at 70°C for 10 min, the solution was 
cooled down to rt, centrifuged and analyzed by CE-SDS with the parameters listed in Table 7. 
Table 7: List of CE-SDS red parameter. 
Parameter Setting 
Auto sampler temperature 20°C 
Injection type Inlet 
Injection voltage 5 kV 
Capillary length 30 cm 
Capillary diameter 50 µm 
Capillary temperature 25°C 
Polarity Reverse 
Voltage 14.2 kV 
Detection 214 nm 
An example CE-SDS red electropherogram of the EndoS2 digestion, with assigned peaks is 
shown in Figure 29. 
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Figure 29: Example CE-SDS red electropherogram of the EndoS2 digestion. 
3.5 Digestion and isolation 
3.5.1 Fab, Fc and LHF 
 
Figure 30: Flow chart of the Fab, Fc and LHF generation and isolation. 
Stability evaluation in digestion buffer with and without reducing solution 
 
Increased pH and temperature are usually used to enforce asparagine deamidation 
in proteins [68] and reducing agents lead to breaking of disulfide bridges and loss of 
tertiary structure. As all three conditions are present in the Kgp digestion, specified 
in the Genovis protocol the rate of deamidation and reduction was evaluated. 
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Deamidation stability: 20.0 µL mIgG1 solution were diluted in 788 µL digestion 
buffer (DB) to 5.00 mg/mL (final pH 7.87), split in two equal portions, kept at rt resp. 
at 37°C/300 rpm for 1, 2 and 24 h and were analyzed by CEX and CE-SDS NR. 
Reduction stability: 20.0 µL mIgG1 solution were pre-diluted in 60.0 µL DB to 
50.5 mg/mL and 24.8 µL of this pre-dilution solution were further diluted in 50 µL 
Genovis reducing solution (RS) and 175.2 µL DB, kept at 37°C/300 rpm for 2 h and 
analyzed by CE-SDS NR. 
Digestion progress of Kgp and influence factors 
 
Enzyme ratio: To assess the initial digestion rate and test the applicability of the 
model, the initial digestion was performed according to the provided protocol from 
Genovis [22]. 20.0 µL mIgG1 solution were diluted in 60.0 µL DB and 24.8 µL 
(1’250 µg) of this solution were further diluted in 50.0 µL DB, 125.8 µL Kgp 10 U/µL 
(1’258 U) and 50.0 µL fresh RS to 5.00 mg/mL mIgG1. The digestion solution was 
incubated at 37°C/300 rpm for 5, 15, 30, 60 and 120 min and tested by CE-SDS NR. 
The 5 min sample was injected twice to prove that digestion stops in presence of 1% 
SDS. 
In the next experiment, the enzyme amount was reduced by a factor of ten. 20.0 µL 
mIgG1 were diluted in 60.0 µL DB and 24.8 µL (1’250 µg) of this stock solution were 
further diluted in 162.7 µL DB, 12.5 µL Kgp 10 U/µL (125 U) and 50.0 µL fresh 
reducing agent to 5.00 mg/mL. The digestion solution was incubated at 
37°C/300 rpm for 5, 15, 30, 60 and 120 min and tested by CE-SDS NR. After first 
data evaluation the experiment was repeated with pull points from 6 to 15 min every 
minute. 
Enzyme inhibition: As the intermediate product LHF is of interest slowing down or 
stopping the digestion progress would simplify the procedure. In this experiment the 
influence of cooling the digestion mixture to rt resp. 5°C, acidifying to pH 5.5 and/or 
addition of cOmplete™ protease inhibitor was evaluated. As extreme pH changes 
(e.g. by spiking TFA) might lead to undesired modifications, the maximum pH drop 
was set to pH 5.5, where most IgG1 are stable. 
20.0 µL mIgG1 were diluted in 60.0 µL DB and 5.00 µL of this pre-dilution, 2.50 µL 
Kgp 10 U/µL and 10.0 µL fresh reducing agent were diluted in 32.5 µL corresponding 
DB, digested for 15 min at 37°C/300 rpm, 22°C or 5°C and analyzed by CE-SDS NR. 
Cysteine influence: To evaluate the influence of cysteine on the enzyme activity 
several digestions at different concentration levels, origins and age were tested and 
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reaction constants compared. As a rate of reduction also the LC peak, at a relative 
migration time (RMT) of 0.54, was observed through the digestion. 
20.0 µL mIgG1 were diluted in 60.0 µL DB to 50.5 mg/mL and the digestion solution 
were prepared as described in Table 8 with the corresponding RS, incubated for 
15 min at 37°C/300 rmp and analyzed by CE-SDS NR. 
Table 8: Dilution table of the cysteine influencing digestion. 
 
µL 
Genovis Self-made/fresh Self-made/7d-
aged 
2.0 mM 0.4 mM 2.0 mM 1.0 mM 0.2 mM 1.0 mM 0.2 mM 
DB pH 8.0 37.5 41.5 37.5 40.0 42.0 40.0 42.0 
mIgG1 
50.5 mg/mL 
5.0 5.0 5.0 5.0 5.0 5.0 5.0 
Kgp 
10 U/mL 
2.5 2.5 2.5 2.5 2.5 2.5 2.5 
RS 20 mM 5.0 1.0 5.0 2.5 0.5 2.5 0.5 
 Genovis 2.0 and 0.4 mM and fresh/self-made 2.0 mM were then repeated in a three 
times larger volume and analyzed after 5, 15, 30, 60 and 120 min. 
To evaluate the reaction kinetics of the Kgp digestion in absence of cysteine 9.9 µL 
mIgG1 (50.5 mg/mL) were diluted in 85.1 µL DB and 5.0 µL Kgp (10 U/µL) were 
added. Afterwards, the digestion mixture was incubated at 37°C/300 rpm for 15, 30 
and 60 min and analyzed by CE-SDS NR. 
pH influence: To be able to evaluate the impact of the pH and better control the 
digestion rate mIgG1 was digested at pH 7.3 (slightly basic) and 6.0 (slightly acidic). 
20.0 µL mIgG1 were diluted in 60.0 µL DB to 50.5 mg/mL and 9.9 μL of this pre-
dilution solution were further diluted in 75.1 μL DB pH 7.3 resp. 6.0, 5.0 μL Kgp 
(10 U/μL) and 10.0 μL RS were added. Afterwards, the digestion mixture was 
incubated at 37°C/300 rpm for 15, 30 and 60 min and analyzed by CE-SDS NR. 
Digestion parameter optimization: To optimally use the reagents included in the 
kit and digest to 20 – 30% LHF within a reasonable time frame the enzyme content 
was set ten times lower compared to the standard protocol and the cysteine 
concentration was reduced to 1.25 mM. pH 6.0 and 8.0 were tested on those 
conditions. 20.0 µL mIgG1 solution were diluted in 60.0 µL DB to 50 mg/mL and 
19.8 μL of this pre-dilution solution were diluted in 157.7 μL DB at pH 6.0 resp. 8.0, 
10 μL Kgp solution (10 U/μL) and 12.5 μL RS were added, incubated at 
37°C/300 rpm for 5, 15, 30, 60 and 120 min and analyzed by CE-SDS NR. 
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Fc isolation: To confirm the identity of the Fc peak (RMT = 0.73) a Protein L affinity 
chromatography (AC) was performed. 20.0 µL mIgG1 were diluted in 60.0 µL DB to 
50.5 mg/mL, 24.8 μL of this pre-dilution solution were further diluted in 187.7 μL DB, 
12.5 μL Kgp (10 U/μL) and 25 μL RS were added and incubated for 2 h at 
37°C/300 rpm. After full digestion a sample of 24 µL was taken for CE-SDS NR, the 
remaining volume was loaded on a Protein L AC pre-equilibrated in binding buffer 
(BB) and eluted with elution buffer (EB) according to Table 9. Acidic elution fractions 
were neutralized with 60 µL 1 M tris pH 8.0 per milliliter fraction. 
Table 9: Elution of Fc isolation. 
 
Number of 
steps 
Volume in mL Buffer Fraction 
volume in mL 
Fraction 
name 
 1 1 BB 1.2 Flow through 
 4 1 BB 4 x 1 Wash 1 – 4 
 5 1 EB pH 3.5 5 x 1 Elution 1 – 5 
 The content of each fraction was determined by Nanodrop. The rinsing fraction was 
concentrated using a 0.5 mL 10K-centrifugal filter, the concentration was determined 
and the purity analyzed by CE-SDS NR. 
SEC screening 
 
To generate material for the preliminary trials 4.00 mg mIgG1 were digested 
according to the optimized conditions and quenched after 30 min with 84 μL 
trifluoroacetic acid 0.5%. 
Number of columns: To evaluate the optimal number of serially connected columns 
required to reach the needed resolution, 40 μg mIgG1 were injected on two and three 
columns in series. 
Column load: To evaluate the maximal injection amount without losing resolution 
40, 120, 200, 300 and 400 µg mIgG1 were loaded on three columns in series. 
Fractionation range: To evaluate an appropriate range to collect desired fractions 
20 runs of 40 µg mIgG1 each were injected on three columns in series and collected 
according to Table 10. Collected fractions were pooled, concentrated with 15 and 
0.5 mL 10K-centrifugal filters and analyzed by Nanodrop and CE-SDS NR. 
Table 10: SEC fractionation range. 
 Fragment name Fraction range in min. 
 IgG 59.0 – 61.0 
 LHF 63.5 – 66.0 
 Fab (+ Fc) 71.5 – 75.0 
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Protein L AC and SEC loading buffer evaluation: To generate fragments free of 
Fc and to stop further fragmentation the digestion was repeated with 8.00 mg mIgG1. 
After 30 min digestion, the mixture was loaded on a Protein L AC column and eluted 
as described in Table 11. Acidic elution fractions were neutralized with 60 µL 1 M tris 
pH 8.0 per milliliter fraction. 
Table 11: Elution of Protein L AC. 
 Number of 
steps 
Volume in mL Buffer Fraction 
volume in mL 
Fraction 
name 
 1 1 BB 1.8 Flow through 
 4 1 BB 4 Wash 
 8 1 EB pH 2.0 8 Elution 
 The concentration of each fraction was measured. Elution fraction 2 – 8 were pooled, 
concentrated with a 15 mL 10K-centrifugal filter to approximately 1 mL and analyzed 
by Nanodrop. 60 µL (413 µg) were analyzed by SEC. 
The sample was then buffer exchanged to SEC mobile phase with a 0.5 mL 10K-
centrifugal filter, rinsed and diluted with 2 x 500 µL mobile phase. Afterwards, the 
content was determined. 8 fraction collection runs of 85 µL (8 x 406 µg) were 
performed. The collected fractions were pooled, concentrated and buffer exchanged 
into formulation buffer in a 4 mL 10K-centrifugal filter to approximately 150 µL 
sample. The fractions were analyzed by Nanodrop and CE-SDS NR. 
Sample stability: To evaluate the sample stability in mobile phase the injection 
sample was analyzed before and after fraction collection (T1d) by CE-SDS NR. 
Digestion reproducibility and fragment isolation: To evaluate the reproducibility 
the digestion was repeated with 4.00 mg mIgG1. After 30 min a sample was 
analyzed by CE-SDS NR. The remaining solution was loaded on a Protein L AC 
column and eluted as described in Table 12. Acidic elution fractions were neutralized 
with 60 µL 1 M tris pH 8.0 per milliliter fraction. 
Table 12: Elution of Protein L AC for reproducibility. 
 Number of 
steps 
Volume in mL Buffer Fraction 
volume in mL 
Fraction 
name 
 1 1 BB 1.4 Flow through 
 4 1 BB 4 Wash 
 10 1 EB pH 2.0 10 Elution 
 The eluate was concentrated and buffer exchanged to approximately 150 µL and 
rinsed with 250 µL formulation buffer. The concentration was measured and the 
samples diluted with additional 800 µL formulation buffer to 3.8 mg/mL. 7 fraction 
collection runs of 100 µL (7 x 380 µg) were performed. The fractions were pooled, 
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concentrated and buffer exchanged into formulation buffer in a 4 and 0.5 mL 10K-
centrifugal filter to approximately 42 µL and rinsed with 2 x 10 µL formulation buffer. 
The fractions were analyzed by Nanodrop and CE-SDS NR. 
Digestion progress of IgdE 
 During the time of this master’s thesis Genovis launched their IgdE product, called 
FabALACTICA™. Its cleavage pattern is the same as Kgps, apart from the cleavage 
site shift of one amino acid. Compared the GingisKHAN®, FabALACTICA™ is 
superior in regard to digestion at neutral pH and absence of reducing agent. However 
it has a lower digestion rate. In this experiment it was evaluated if IgdE is suitable for 
LHF generation. 
10.0 µL mIgG1 solution was pre-diluted in 40.5 µL IgdE DB to 40.0 mg/mL, 5.0 µL of 
this pre-dilution solution (200 µg) were further diluted in 10.0 µL DB to 10 mg/mL and 
5.0 µL IgdE 40 U/µL (200 U) were added, incubated at 37°C/300 rpm for 3 h and 
analyzed by CE-SDS NR. 
This procedure was repeated with 800 µg mIgG1 and analyzed after 30, 50, 60 and 
90 min and a third time for time points at 5, 10, 15, 20 and 25 min. 
3.5.2 F(ab’)2 
 
Figure 31: Flow chart of the F(ab)2 generation and isolation. 
IdeS digestion and Protein L AC pH 3.5 elution 
 
The IdeS digestion was performed according to the Genovis protocol. 4.95 µL mIgG1 
were diluted with 80.0 µL DB and 15.0 µL IdeS (66.7 U/mL) were added. The solution 
was incubated at 37°C/300 rpm for 30 min. After the digestion a sample of 18.0 µL 
was taken and analyzed by CE-SDS NR. 
Afterwards the Protein L AC was performed according to GE Healthcare Instructions 
29-0078-77 AC [69]. The digestion mixture was loaded on the column and eluted as 
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listed in Table 13. Acidic elution fractions were neutralized with 60 µL 1 M tris pH 8 
per milliliter buffer. 
Table 13: Elution of Protein L AC after IdeS digestion. 
 
Number of 
steps 
Volume in mL Buffer Fraction 
volume in mL 
Fraction 
name 
1 0.6 BB 0.68 Flow through 
5 1.0 BB 5 x 1 Wash 
5 1.0 EB 5 x 1 Elution 
 The content of each fraction was determined by Nanodrop. Flow through and wash 
fraction 1 were pooled, concentrated with 4 and 0.5 mL 10K-centrifugal filter to 
approximately 20 µL, rinsed with 20 µL formulation buffer and analyzed by CE-SDS 
NR. All elution fraction were pooled, concentrated with 4 and 0.5 mL 30K-centrifugal 
filter and rinsed with 2 x 10 µL formulation buffer. Concentration of both samples 
were determined. 
Over-digestion screening and Protein L AC pH 2.0 – 3.0 elution 
 
To check whether the digestion is complete after 30 min and exclude over-digestion, 
the digestion time was extended to 60 min. To evaluate the correct pH value to elute 
the F(ab’)2 fragment from the column a stepwise elution gradient of pH 3.0, 2.5 and 
2.0 was applied. 
The digestion conditions are identical to the digestion before. After 60 min digestion 
a sample of 18.0 µL was taken for CE-SDS NR and the remaining volume was 
loaded on the Protein L column, washed and eluted according to Table 14. 
Table 14: Protein L AC purification table. 
 Number of 
steps 
Volume in mL Buffer Fraction 
volume in mL 
Fraction name 
 2 (vial rinse) 0.45 BB 1 Flow through 
 4 1.0 BB 4 Wash 
 8 0.25 
EB pH 3.0 5 pH 3.0 elution 
 3 1.0 
 8 0.25 
EB pH 2.5 5 pH 2.5 elution 
 3 1.0 
 8 0.25 
EB pH 2.0 5 pH 2.0 elution 
 3 1.0 
 The protein content of each fraction was determined. The flow through, wash and all 
fractions of the identical EB (pH 2.5 and 2.0) were pooled individually, concentrated 
with a 4 and 0.5 mL 10K-centrifugal filter and each sample was analyzed by 
Nanodrop and CE-SDS NR. 
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FragIT™ kit digestion and fragment isolation 
 
For simple enzyme removal and F(ab’)2 isolation Genovis offers the FragIT™ kit, 
containing agarose-immobilized IdeS and a CaptureSelect™ column with an 
immobilized 13 kDa lama antibody fragment [70]. The digestion and fragment 
isolation were performed according to the FragIT™ kit instructions [70] including Fc/2 
elution and all steps for maximal recovery. To evaluate if the columns could be 
reused the whole procedure was repeated at the same day and after 17 days. 
49.5 µL mIgG1 solution (10 mg IgG) were diluted with 450 µL DB to 20 mg/mL, 
loaded on the digestion column and rotated end-over-end for 30 min at rt. Afterwards 
the solution was collected through centrifugation at 100 g for 1 min and the column 
was washed with 2 x 1 mL BB. The content was determined and a sample for CE-
SDS NR was taken. The solution was loaded on the CaptureSelect™ column, rotated 
end-over-end for 30 min at rt, collected by centrifugation at 200 g for 1 min and 
washed with 2 x 1 mL BB. The Fc/2 was collected through re-suspending with 
2 x 1 mL CaptureSelect™ EB and collecting at 200 g resp. 1000 g at the final step. 
Afterwards, the fractions (4.5 mL F(ab’)2 and 2.5 mL Fc/2-fraction) were 
concentrated and buffer exchanged to formulation buffer with 4 and 0.5 mL 10K-
centrifugal filter to approximately 42 µL and rinsed with 3 x 20 µL. Samples were 
analyzed by Nanodrop and CE-SDS NR. This procedure was repeated after 150 min 
and 17 days. 
3.5.3 Chitobiose cleavage 
 
Figure 32: Flow chart of the EndoS2 digestion and fragment isolation. 
EndoS2 digestion 
 
The EndoS2 digestion was performed according to the Genovis protocol [24] at 
20 mg/mL. For stability reasons the pH of the DB was set to 6.5. 
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5.90 µL mIgG1 (1.19 mg) were diluted in 24.1 µL DB and 30.0 µL EndoS2 40 U/µL 
(1’200 U) added. The solution was incubated at 37°C/300 rpm for 30 min. After the 
digestion a sample of 9.0 µL analyzed by CE-SDS red. The remaining digestion 
mixture was buffer exchanged with a 100 K-spin filter, the membrane was rinsed with 
2 x 20 µL fresh formulation buffer and the sample was analyzed by Nanodrop and 
CE-SDS red. 
Immobilized GlycINATOR® 
 
To ensure complete enzyme removal immobilized EndoS2 (immobilized 
GlycINATOR® MidiSpin) is used for digestion. The digestion was performed 
according the Genovis standard protocol for A0-GL6-100 Version 17.1.1 [71] 
including steps for maximum recovery. 
49.5 µL mIgG1 (10 mg) were diluted in 450.5 µL DB, loaded on the equilibrated 
column and rotated end-over-end for 30 min at rt. Afterwards, the solution was 
collected through centrifugation at 100 g for 1 min and the column was washed with 
2 x 1 mL BB. All fractions were pooled, concentrated and buffer exchanged into 
formulation buffer with 4 and 0.5 mL 10K-centrifugal filters to approximately 42 µL. 
The filter was rinsed with 2 x 20 µL formulation buffer and the sample was analyzed 
by Nanodrop and CE-SDS red. 
3.6 Ecology, safety and disposal 
Standard laboratory safety equipment consisting of lab coat and protective goggles were used 
during all tasks. During acid or base handling regular nitrile and during handling of organic 
solvents butyl gloves were used. Contaminated solutions and consumables were discarded in 
the chemical waste container. Powdered SDS and 2-mercaptoethanol were only handled 
under the hood, as SDS creates irritating dust and 2-mercaptoethanol creates toxic fumes and 
may be fatal in contact with skin [72]. 
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4 Results and discussion 
4.1.1 Fab, Fc and LHF 
Stability evaluation in digestion buffer with and without reducing solution 
 
Deamidation stability: A negligible deamidation rate of < 0.5% was detected within 
the two hours in DB for both temperatures. However after 24 h an increase of 0.7 
and 2.6% was detected for rt and 37°C, respectively. The chromatogram is shown in 
the appendix on p. VII. Neither fragmentation nor aggregation was detected by CE-
SDS NR during the measured time frame.  
Stability in digestion buffer 
 
 
Figure 33: Purity trend of the stability in digestion buffer 
by CEX (deamidation). 
 
Figure 34: Purity trend of the stability in digestion buffer 
by and CE-SDS NR (fragmentation/aggregation). 
 Reduction stability: The relative area increase of the sum of reduced species (L, 
H, HL, HH, and HHL) after 2 h at 37°C is below 0.1% and therefore consider non-
critical. The electropherogram overlay is displayed in Figure 35. 
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Figure 35: CE-SDS NR electropherogram of the mIgG1 stability in digestion buffer with reducing agent. 
Digestion progress of Kgp and influence factors 
 Enzyme ratio: The consistency of the CE-SDS NR double injection of the digestion 
sample after 5 min proves, that the digestion stops in presence of 1% SDS. The 
digestion according to the Genovis protocol is almost complete after 5 min (appendix 
p. VII) and is therefore not suitable for the generation of LHF. With the adjusted 
enzyme-protein ratio of 1:10 a maximum LHF concentration of 24 area% is reached 
after 14 min and the digestion is complete after 2 h. Linear regression of the kinetic 
ln([A]/[A]0) VS. time-plot, displayed in the appendix on p. VIII shows a coefficient of 
determination (R2) of 0.9683. This high value is an indication of first order-like 
behavior [66]. A comparison of the measured and the simulated values, presented 
in Figure 36, shows a good overlap of the IgG1 and LHF curve. Fc and Fab 
concentrations are slightly overestimated by the simulation. As the generation of LHF 
has priority over Fc and Fab this model is considered fit for purpose. 
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Figure 36: CE-SDS NR purity progress of the 1:10 Kgp-to-IgG digestion and comparison of the simulated values. 
 Enzyme inhibition: An evaluation of the reaction constant k1 (see Figure 37) and 
tmax(LHF) (see Figure 38) revealed following inhibition potential: 
Cooling > Acidify to pH 5.5 > cOmplete™ 
 
Figure 37: Reaction constant k1 in dependency of 
temperature for tested inhibitory factors (standard 
digestion, cOmplete™ and pH 5.5). 
 
Figure 38: Calculated time point of maximal LHF 
concentration in dependency of temperature for tested 
inhibitory factors (standard digestion, cOmplete™ and 
pH 5.5). 
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 The cOmplete™ protease inhibitor cocktail will be omitted for further studies, as the 
inhibition potential is low. Additionally, as the composition is not clearly defined 
tracking during fragment isolation and full removal cannot be ensured. For further 
studies cooling to 5°C potentially in combination with acidifying and enzyme removal 
for minimal molecule impact will be applied. 
Cysteine influence: The comparison between digestions a different cysteine 
concentrations, shown in Figure 39 and Figure 40, revealed a high influence of 
cysteine on the Kgp digestion rate. The Kgp digestion rate is drastically reduced resp. 
the digestion time is increased in absence of cysteine. 
 
 
Figure 39: Kinetic constants of the Kgp digestion for 
different cysteine concentration of Genovis, self-
made/fresh and self-made/aged RS. 
 
Figure 40: Calculated time point of maximal LHF 
concentration of the Kgp digestion for different cysteine 
concentration of Genovis, self-made/fresh and self-
made/aged RS. 
 The self-made cysteine solution had the highest digestion rate resp. lowest digestion 
time for all concentrations compared to other conditions. The digestion using aged 
self-made cysteine solution was slower than freshly made RS for all concentrations. 
The highest digestion rate and lowest digestion time was determined at a 
concentration of 1 mM, even though similar results were obtained for a concentration 
of 2 mM cysteine. A possible explanation for the lower kinetic constant of Genovis’ 
RS compared to the self-made might be small differences regarding final 
concentration. The cysteine in aged RS is most probably partly oxidized and not able 
to provide the optimal reducing environment anymore. 
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The purity progress of the peak at RMT 0.54 through the digestion time, displayed in 
Figure 41, shows a comparable pattern for all tested cysteine concentrations. The 
purity initially increases and later decreases again. As expected, the rate of reduction 
increases with increasing cysteine content, but is throughout low. All experiments 
using the RS of Genovis show a purity maximum at 30 min, whereas the self-made 
RS shows its maximum after 60 min, which is significant higher compared to the 
Genovis RS at equivalent concentration. This is an indication that this peak does not 
only contain LC but also another unidentified species, which is formed and degraded 
during the digestion. 
 
Figure 41: Progress of the 25 kDa-peak formation during the IgG1 Kgp digestion at different cysteine 
concentrations. 
 Therefore the cysteine concentration is considered crucial for the digestion progress 
and Genovis and self-made RS do not deliver equal results. 
pH influence: The experiment showed that the pH has a large impact on the 
digestion kinetic. At pH 8.0 the highest and at pH 6.0 lowest kinetic constant was 
measured. This is visualized in Figure 42 and Figure 43. 
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pH influence 
 
Figure 42: Kinetic constants of the Kgp digestion at 
different pH. 
 
Figure 43: Calculated time point of maximal LHF 
concentration of the Kgp digestion at different pH.
 Digestion parameter adjustment: It was observed that upon reconstitution of the 
cysteine according to the Genovis protocol, a suspension was obtained. The cysteine 
only fully dissolved after further dilution for digestion. The purity of IgG, LHF, Fc and 
Fab at pH 6.0 and 8.0 are visualized in Figure 44 and Figure 45, respectively. The 
digestion at pH 6.0 is relatively slow and the maximum concentration of LHF is not 
reached until the upper time limitation of 120 min. The digestion at pH 8.0 on the 
other hand shows a maximum LHF concentration after 30 min followed by a shallow 
decrease, allowing the scientist to perform the digestion in a reasonable time frame. 
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Digestion parameter adjustment 
 
Figure 44: Digestion course of the parameter adjusted 
Kgp digestion at pH 6.0. 
 
Figure 45: Digestion course of the parameter adjusted 
Kgp digestion at pH 8.0. 
 Fc isolation: The Protein L AC successfully bound the Fab and the Fc could be 
collected with a recovery of 47%. Later Fab elution, displayed in Figure 46, was 
minimal with a recovery of 20%. A possible explanation is, that the pH of the EB was 
not low enough to reverse the binding. 
 
Figure 46: Protein content of the Protein L affinity chromatography by Nanodrop. 
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 The Fc could successfully be isolated with a final concentration of 3.43 mg/mL by 
Protein L AC and the peak at RMT 0.73 in CE-SDS NR could be assigned. The 
corresponding electropherogram is shown in Figure 47. 
 
Figure 47: CE-SDS NR electropherogram of the Kgp digestion and concentrated Protein L flow through. 
SEC screening 
 Number of columns: Two SEC columns in series are capable of separating IgG, 
LHF and Fab. Three columns in series prolong the run time from 55 to 85 min, 
increase the resolution and an additional peak between LHF and Fab could be 
separated. Baseline separated is not reached in both cases. Corresponding 
chromatograms are shown in Figure 48. 
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Figure 48: SEC chromatogram overlay of 2 and 3 columns in series. 
 Column volume: Testing column loads from 40 to 400 μg mIgG1 showed no 
significant loss of peak resolution. The SEC chromatogram overlay is displayed in 
Figure 49. 
 
Figure 49: SEC chromatogram of the injection amount evaluation. 
 Fractionation range: The chosen fractionation range was sufficient to isolate the 
desired fragments. Importantly, the chromatographic overlays (Figure 50) revealed, 
that the TFA spiking did not fully quench the digestion and the sample did 
fragmentation continued at 5°C (shown by decreasing peaks at retention time 59.6 
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(IgG) and 64.5 min (LHF) as well as an increase in the Fab peak at retention time 
72 min). 
 
Figure 50: SEC chromatogram overlay of the fraction collection trial of 20 times 40 μg injection. 
 A summary of the isolated fragment is listed in Table 15. 
Table 15: Summary of isolated fragments during SEC trials. 
 Fragment Volume in 
µL 
Conc. In 
mg/mL 
Mass in µg Recovery 
in % 
Purity in 
A% 
IgG1 120 0.10 11 4 86 
LHF 120 0.18 22 14 75 
Fab+Fc 120 0.81 64+32 45+30 98 
 
Figure 51: CE-SDS NR overlay of the isolated IgG, LHF and Fab+Fc fractions. 
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Protein L AC and SEC loading buffer evaluation: The Protein L AC could 
successfully remove the Fc part and the enzyme (see appendix p. VIII) and stop 
further digestion. As a trade-off, a small amount of IgG, LHF and Fab was lost during 
the wash steps. The intact IgG purity by CE-SDS NR was higher than expected. 
Reason for this could possibly be a slower digestion rate and imply issues regarding 
reproducibility. Telquel injection on the SEC showed a different chromatographic 
pattern, displayed in Figure 52, than previous injections without prior Protein L AC. 
A possible explanation for this behavior is the different buffer composition influencing 
the hydrodynamic radius. 
 
Figure 52: SEC chromatogram of the Kgp digestion fragment isolation with and without Protein L AC. 
 Prior buffer exchange into SEC mobile phase improved pattern resemblance on the 
SEC column, shown in Figure 53. Peaks before the IgG peak indicate sample 
instability of mixed sample but also isolated fragments. The lower UV trace of one of 
the sample injections can be explained by a smaller injection volume. A summary of 
isolated fragments is listed in Table 16. Reason for the low LHF purity is the relatively 
high IgG content in the initial sample tailing into the LHF fraction. 
Table 16: Summary of isolated fragments during SEC injection buffer evaluation. 
 Fragment Volume in 
µL 
Conc. In 
mg/mL 
Mass in µg Recovery 
in % 
Purity in 
A% 
IgG1 130 4.55 591 89 98 
LHF 110 1.29 142 21 45 
Fab 110 1.24 136 15 95 
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Figure 53: SEC chromatogram overlay of the fragment isolation after Kgp digestion, Protein L AC and buffer 
exchange in mobile phase. 
 Sample stability: The CE-SDS NR electropherogram of the SEC injection sample 
before and after fraction collection, displayed in Figure 54, shows no significant 
changes. A possible explanation are reversible aggregates, which dissociate in CE-
SDS NR sample buffer. 
 
Figure 54: CE-SDS NR electropherogram of initial and one-day  aged injection sample. 
 Digestion reproducibility and fragment isolation: CE-SDS NR comparison of two 
digestions with identical parameters but different GingisKHAN® batches (see Figure 
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55) showed inconsistent digestion progress. A possible explanation for this are 
differences of the RS, as a different solubility was overserved during reconstitution. 
 
Figure 55: CE-SDS NR electropherogram overlay of two Kgp digestions with identical parameter apart from 
different GingisKHAN® batches. 
 Buffer exchange into formulation buffer improved the sample stability and less peaks 
before IgG were observed. 
 
Figure 56: SEC chromatogram overlay of the fragment isolation after Kgp digestion, Protein L AC and buffer 
exchange in formulation buffer. 
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 A summary of isolated fragments is listed below. 
Table 17: Summary of isolated fragments during SEC fraction collection. 
 Fragment Volume in 
µL 
Conc. In 
mg/mL 
Mass in µg Recovery 
in % 
Purity in 
A% 
IgG1 20 6.21 124 4 97 
LHF 20 2.24 45 9 41 
Fab 20 2.32 46 15 82 
 
Digestion progress of IgdE 
 The IgdE digestion progress, displayed in Figure 57, showed a much lower digestion 
time required than the 16 –18 h suggested in the Genovis protocol. The maximum 
LHF concentration of 29% was detected after 10 min and would even allow reduction 
of the enzyme-to-protein ratio to slow down the digestion. The higher intermediate 
concentration, the poly-his tag for simple enzyme removal and mild digestion 
conditions make IgdE superior to Kgp for the LHF generation. 
 
Figure 57: Digestion progress of IgdE by CE-SDS NR. 
4.1.2 F(ab’)2 
IdeS digestion and Protein L AC pH 3.5 elution 
 The IdeS digestion was complete after 30 min. Fc/2, IdeS and some other, minor 
impurities could successfully be removed by the Protein L AC. The F(ab’)2 could not 
be eluted with EB at pH 3.5. 
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Over digestion screening and Protein L AC pH 2.0 – 3.0 elution 
 After 1 h of digestion no sign of over-digestion could be detected by CE-SDS NR. 
Elution at pH 3.0 was very slow, at pH 2.5 moderate and at pH 2.0 acceptable. The 
electropherogram is displayed in the appendix on p. IX. 
 
Figure 58: Elution profile of Protein L AC at pH 3.0, 2.5 and 2.0. 
FragIT™ kit digestion and fragment isolation 
 The on-column IdeS digestion was complete after 30 min and the Fc/2 could 
successfully be removed with the CaptureSelect™ column, as shown in Figure 59.  
 
Figure 59: CE-SDS NR electropherogram of the IdeS digestion and isolated products. 
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 Initial and second digestion at the same day show the same digestion rate. The 
digestion after 17 days showed a loss in activity and is after 30 min not complete. No 
differences of digestion products was observed. A summary of the isolated fragments 
is listed in Table 18. 
Table 18: Summary of isolated fragments for FragIT™ kit digestion and fragment isolation. 
 
Run Volume in 
µL 
Conc. in 
mg/mL 
Mass in µg Recovery 
in % 
Purity in 
A% 
1 100 31.65 3’165 48 91 
2 100 36.12 3’612 55 96 
 3 100 12.71 1271 19 97 
 
Figure 60: CE-SDS NR electropherogram overlay of the three FragIT™ digestion. 
4.1.3 Chitobiose cleavage 
EndoS2 digestion 
 The digestion according to the Genovis® protocol and the subsequent buffer 
exchange were successful. The enzyme could not be removed but reduced to below 
0.5%. 40 µL chitobiose-cleaved mIgG1 27.06 mg/mL (1’082 µg = 94% yield) could 
be isolated. 
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Figure 61: CE-SDS red. electropherogram of the EndoS2 digestion and buffer exchange. 
Immobilized GlycINATOR® 
 The Genovis® digestion procedure for the immobilized GlycINATOR® was 
successfully applied to mIgG1. The digestion product was be concentrated and 
buffer exchanged into formulation buffer. 62 µL chitobiose-cleaved mIgG1 at 
125 mg/mL (7’750 µg = 80% yield) were isolated. 
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5 Conclusion 
The influence of the undesired modifications, deamidation and reduction during digestion 
where assessed and are considered minimal (> 0.5%) within 2 The Kgp digestion of the mIgG1 
using GingisKHAN® was successful and the LHF could be detected as intermediate by CE-
SDS NR after reducing the enzyme-to-protein ratio to 1:10. Cysteine concentration and pH of 
the DB was classified as a crucial influence parameter for the digestion kinetic. Through 
digestion parameter optimization for LHF isolation the time for the maximal LHF was adjusted 
to 30 min at 37°C, which is considered an appropriate time frame to handle. Of the evaluated 
digestion inhibition parameter (temperature, pH and cOmplete™ inhibitor cocktail) nothing fully 
inhibited but slowed down further fragmentation. Inhibition potential is in decreasing order: 
cooling to 5°C, acidify to pH 5.5 and adding cOmplete™. Therefore enzyme removal by AC is 
proposed to stop further digestion. Through Protein L AC the Fc could be isolated and following 
elution at pH 2.0 the IgG, LHF and Fab mixture could be eluted. Small quantities could be 
separated by SEC with a purity of > 75%. Scale-up and reproducibility experiments revealed 
issues regarding inconsistent digestion progresses for different batches. Slow digestion led 
finally to large IgG contamination of the LHF fraction. This digestion kinetic variations probably 
origin from RS differences. Experiments on the recently launched FabALACTICA™ (IgdE) 
showed promising results with an acceptable digestion time, mild digestion conditions, less 
influencing factors and a poly-his tag on the enzyme for simple removal and digestion stop. 
Also the outlook on the immobilized IgdE, which is according to Genovis® supposed to be 
launched in fall 2017 makes IgdE and better alternative for LHF generation than Kgp. 
Digestion with FabRICATOR® (soluble IdeS) was complete after 30 min and Fc/2 was removed 
by Protein L AC. The F(ab‘)2 was successfully generated by applying standard FragIT™ 
(immobilized IdeS) procedure and the desired fragment was isolated by CaptureSelect™ 
without exposure to acidic solution. The maximal recovery was 55% and purity 96% and no 
undesired modifications were detected. The procedure was repeated with identical outcome 
at the same day using the same mab and digestion kit. 
The chitobiose cleavage by GlyCINATOR® (soluble EndoS2) was complete after 30 min at 
37°C but a simple 100K-centrifugal filtration was not sufficient to fully remove the enzyme. 
Immobilized GlyCINATOR® provided a full digestion after 30 min at rt and full enzyme removal 
with a yield of 80%. 
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6 Outlook 
Following experiments should include identification and in-depth analysis of undesired 
modification by mass spectrometry. 
Also other types of IgG1, mutants, other applicable subclasses or proteins should be tested on 
the implemented methods. 
As soon as the immobilized FabALACTICA™ (IgdE) is launched, digestion progress and 
applicability for the LHF generation should be evaluated. Important is also a reproducibility and 
batch-to-batch comparison. 
Isolated digestion products have to be tested for regarding CQA. This could include: cell 
bioassay for fragments and higher order structure analysis by differential scanning calorimetry 
and circular dichroism in the far UV for the chitobiose chelated product. 
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I. Mechanism of action 
Table 19: Most important effector functions of IgG. 
Function Mechanism 
Complement activation After epitope binding on a cell an IgG undergoes a conformational 
change. Two bound Igs next to each other allow for binding of 
C1q, a protein complex, at the CH2 (Glu318, Lys320, Lys322). 
Subsequently, the complement cascade is initiated, which leads to 
pore formation and finally the destruction of the cell [25,73]. 
Ab-dependent cellular 
cytotoxicity (ADCC) 
Cell bound IgGs allow natural killer-cells to bind the Fc region with 
a Fc receptor (FcR), the FcRs are cross-linked and initiate the 
release of granzymes and leading to apoptosis of the cell [25,74]. 
Opsonization Igs bound to bacteria present their Fc part to phagocytes and 
simplify the internalization [25]. 
Blocking Ig binding to a receptor may prevent the access for ligands and 
their physiological function [25]. 
A special form of blocking is the binding of an Ig to the CDR of 
another Ig, so called anti idiotypic Ab. This leads to the elimination 
of this respective Ab [25]. 
Masking Binding of non-cytotoxic Ig may prevent cytotoxic T-cells resp. Igs 
to recognize and bind an antigen [25]. 
Neutralization Small molecular toxins might act as an antigen and through 
binding by an Ig the binding to a receptor and the toxic effect is 
prevented [25]. 
Receptor binding Ab binding to a receptor can have three possible effects: 
 No reaction The receptor is not effected by the Ab [25]. 
 Agonistic Ab The Ig binding itself imitates a ligand binding and triggers a 
response. This effect is only relevant for auto-immune disease 
[25]. 
 Antagonistic Ab  The Ig blocks the access of the receptor for ligands and prevents a 
physiological reaction [25]. 
Inhibition Some specific soluble immune complexes have the ability to 
suppress the activation of B-cells. This is important to reduce the 
antigen specific B-cell response [25]. 
Penetration Igs are able to cross polarized epithelial cells through cell-
mediated transcytosis. For IgG the neonatal Fc receptor (FcRn) is 
of importance and even allows passing of the placenta [25,75]. 
Precipitation Binding of polyclonal Ab on multiple epitopes first forms soluble 
complexes and leads later to precipitation [25]. 
Agglutination Linking multiple particular antigens, e.g. on the surface of cells, 
leads to clump [25]. 
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II. Enzymes in mab analytics 
I.1. Fragmentation 
Table 20: List of Ig fragmenting enzymes. 
Application Name Trade name Information 
Fab + Fc Papain Papain Cleaves hydrophilic-R/K ↓ not V 
[76]. Over-digestion possible. 
Lys-C Lys-C Cleaves C-terminal of K. Over-
digestion possible. [77] 
SpeB FabULOUS™ Cleaves human IgG1: 
KTHT ↓ CPPCPAPEL under 
reducing conditions. [78] 
Kgp GingisKHAN® Cleaves human IgG1: 
KSCDK ↓ THTCPPCP under mild 
reducing conditions. 
IgdE FabALACTICA™ Cleaves IgG1: 
KSCDKT ↓ HTCPPCP [23] 
F(ab’)2 Pepsin Pepsin Cleaves the peptide bond of 
hydrophobic and aromatic amino 
acids [79]. Risk of oxidation. 
IdeS FabRICATOR® Cleaves human IgG1, 3 and 4: 
CPAPELLG ↓ GPSVF and human 
IgG2: CPAPPVA ↓ GPSVF. [21] 
Peptide mapping Trypsin Trypsin Cleaves C-terminal of K/R-not P 
[80]. 
Rgp GingisREX™ Cleaves C-terminal of R [81]. 
Removal of C-
terminal K 
Carboxypeptidase 
B 
Carboxypeptidase 
B 
Cleaves K and R at the C-terminus 
[80]. 
 
I.2. Deglycosylation 
Table 21: List of Ig deglycosylating enzymes. 
Cleavage site Name Trade name Information 
-GlcNAc | Asn- PNGase F PNGase F Complex, high-mannose and 
hybrid type oligosaccharides of 
N-linked glycoproteins [80]. 
-GlcNAc | GlcNAc- EndoS IgGZERO® Only complex oligosaccharides 
of IgG and the α1-acid 
glycoprotein [82]. 
-GlcNAc | GlcNAc- EndoS2 GlycINATOR® Complex, high-mannose and 
hybrid type oligosaccharides of 
IgG and the α1-acid glycoprotein 
[82]. 
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Removal of α2,3-, 
α2,6- and α2,8-
linked sialic acids 
Two sialidase of 
Akkermansia 
muciniphila 
SialEXO™ Cleaves N- and O-glycans[82]. 
O-glycosylated 
proteins of core 1 
and core 3 
endo-α-N-
acetylgalactos-
aminidase 
OglyZOR™ Required prior sialic aids 
removal [82]. 
O-glycosylated 
proteins N-
terminally of the 
S/T glycosylation 
site 
Endoprotease of 
Akkermansia 
muciniphila 
OpeRATOR™ Improved enzyme activity with 
removed sialic aids [82]. 
 
III. Instruments 
Table 22: List of used instruments. 
Type Model Manufacturer 
Centrifuge 0.5 mL tubes 1-14 SIGMA 
Centrifuge 4 & 15 mL tubes 3-18KS SIGMA 
CE-SDS NR/Red. PA800plus Pharmaceutical 
Analysis System 
BECKMAN COULTER 
HPLC (CEX and SEC) 1100 Series Agilent Technology 
HPLC fraction collector 1260 Infinity Agilent Technology 
Thermo shaker Thermomixer comfort EPPENDORF 
Tube rotator plate Tube rotator BOEKEL 
Water bath Eco Silver Lauda 
Nanodrop™ NanoDrop1000 
Spectrophotometer 
Thermo Scientific™ 
 
IV. Consumables 
Table 23: List of used consumables. 
Description Manufacturer Item number 
Amicon® Ultra – 0.5mL 
Centrifugal Filters 
Ultracel® - 10K 
Merk UFC501096 
Amicon ® Ultra – 4 
Centrifugal Filters 
Ultracel® - 10K 
Merk UFC801024 
Amicon ® Ultra – 15 
Centrifugal Filters 
Ultracel® - 10K 
Merk UFC901096 
Stericup® 150ml 
Millipore® Express PLUS 
Millipore SCGPU01RE 
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0.22µm PES 
Protein L affinity 
chromatography 
HiScreen™ Capto™ L 
HiTrap™ Protein L, 1 mL 
GE Healthcare 29048665 
Crimp vials 6 mL + 20 mm 
crimp caps with septum 
Agilent Technology 9301-1419 + 9301-1425 
 
V. Reagents 
Table 24: List of used reagents. 
Name Supplier Part number Purity / Conc. MW in g/mol 
2-
mercaptoethanol 
SIGMA-ALDRICH 63689 ≥ 99.0% 78.13 
cOmplete™ 
protease inhibitor 
cocktail 
Roche 11 697 498 001 n.a. n.a. 
Cysteine SIGMA-ALDRICH 30089 98.5% 121.16 
Hydrochloric acid Merk 1.09060 1 M 36.46 
Iodoacetamide SIGMA-ALDRICH I1149 ≥ 99% 184.96 
L-Histidine SIGMA-ALDRICH H8000 ≥ 99% 155.15 
L-Histidine 
hydrochloride 
monohydride 
SIGMA-ALDRICH H8125 ≥ 98% 209.63 
ortho-phosphoric 
acid 
Merk 1.00552 85% 97.99 
Potassium 
chloride 
SIGMA-ALDRICH P9541 ≥ 99.0% 74.55 
SDS-MW Gel 
buffer 
BECKMAN 
COULTER 
A30341 n.a. n.a. 
Sodium chloride Honeywell | Fluka 71380 ≥ 99.5% 58.44 
Sodium hydroxide 
solution 
Merk 1.09137 1 M 40.00 
Sodium 
phosphate dibasic 
anhydrous 
SIGMA-ALDRICH S7907 ≥ 99.0% 141.96 
Sodium 
phosphate 
monobasic 
monohydrate 
SIGMA-ALDRICH 71507 ≥ 99.5 137.99 
Trifluoroacetic 
acid 
Thermo Scientific 28903 Sequencing grade 114.02 
Tris-HCl Promega H5123 ≥ 99.0% 157.56 
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Trisodium citrate 
dihydrate 
SIGMA-ALDRICH S1804 100% 294.10 
Trizma® base SIGMA-ALDRICH T1503 99.9% 121.14 
UltraPure™ Tris-
HCl pH 8.0 
Gibco 15568025 1 M 157.60 
 
VI. Enzymes 
Name Supplier Part number Amount in units MW in kDa 
FabALACTICA™ Genovis A0-AG1-020 2000 70 
FabRICATOR® Genovis A0-FR1-020 2000 38 
FragIT™ kit 
midispin 
Genovis A0-FR6-100 n.a. 38 
GingisKHAN® Genovis B0-GKH-020 2000 50 
GlyCINATOR® Genovis A0-GL1-020 2000 92 
Immobilized 
GlycINATOR® 
MidiSpin 
Genovis A0-GL6-100 n.a. 92 
 
VII. Software 
Table 25: List of used software. 
Name Version Developer 
ChemDraw Ultra 14.0 PerkinElmer 
Chromeleon 6.8 Thermo Scientific™ 
GPMAW 10.0 Lighthouse data 
Open Lab CDS 
Chemstation Edition 
for LC & LC/MS Systems 
C.01.05 [41] Agilent Technologies 
PyMOL Molecular Graphics 
System 
1.5.0.5 SCHRÖDINGER 
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VIII. Chromatogram and electropherogram 
I.3. Fab, Fc and LHF 
Stability evaluation in digestion buffer with and without reducing solution 
 
Figure 62: CEX chromatogram of the digestion buffer stability at 37°C. 
 
Figure 63: Digestion progress of the digestion according to Genovis® standard protocol. 
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Figure 64: Kinetic model plot ln([A]/[A]0) in dependency of time to justify a first order kinetic model. 
 
Figure 65: CE-SDS NR electropherogram of the Protein L AC flow through and elution. 
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I.4. F(ab’)2 
 
Figure 66: CE-SDS NR electropherogram of the IdeS digestion and Protein L AC. 
I.5. Chitobiose cleavage 
 
Figure 67: CE-SDS red electropherogram of the digestion by immobilized EndoS2 and buffer excahnged sample. 
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